Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
USA

Back

Killing the Messenger: Antisense DNA and siRNA

Author(s): M. Nesterova and Y. S. Cho-Chung

Affiliation: Chief, Cellular Biochem. Section, BRL, CCR, National Cancer Institute, Head, NIH TherapeuticOligo. Int. Group, Bldg. 10, Rm. 5B05, 9000 Rockville Pike, Bethesda, MD 20892-1750, USA.

Abstract:

Among the technologies available for gene knockdown RNase H-dependent antisense oligonucleotides and RNAi are very popular. Both offer specificity and efficient knockdown of the genes; both are useful tools to study gene functions. Antisense and RNAi methods share many practical problems such as site selection, toxicity at high concentration, and the difficulty of transfection in certain cell types. We will focus in this review on the most important issues in the development of both methods and their possible use in gene-silencing therapy.

Keywords: gene therapy, gene silencing, oligonucleotides, antisense, rna interference

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 5
ISSUE: 8
Page: [683 - 689]
Pages: 7
DOI: 10.2174/1389450043345137
Price: $58